News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,191 Results
Type
Article (42259)
Company Profile (436)
Press Release (670496)
Multimedia
Podcasts (76)
Webinars (13)
Section
Business (208711)
Career Advice (2021)
Deals (36003)
Drug Delivery (104)
Drug Development (83566)
Employer Resources (173)
FDA (16421)
Job Trends (15091)
News (352742)
Policy (33070)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2642)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50930)
ALS (92)
Alzheimer's disease (1420)
Antibody-drug conjugate (ADC) (127)
Approvals (16409)
Artificial intelligence (257)
Autoimmune disease (24)
Automation (15)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (105)
Biotechnology (330)
Bladder cancer (65)
Brain cancer (26)
Breast cancer (270)
Cancer (2143)
Cardiovascular disease (179)
Career advice (1687)
Career pathing (29)
CAR-T (150)
Cell therapy (426)
Cervical cancer (19)
Clinical research (67634)
Collaboration (838)
Compensation (516)
Complete response letters (24)
COVID-19 (2642)
CRISPR (42)
C-suite (235)
Cystic fibrosis (105)
Data (2083)
Decentralized trials (2)
Denatured (27)
Depression (47)
Diabetes (261)
Diagnostics (6408)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (105)
Drug shortages (26)
Duchenne muscular dystrophy (98)
Earnings (87578)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115448)
Executive appointments (712)
FDA (17626)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (754)
Gene editing (109)
Generative AI (20)
Gene therapy (312)
GLP-1 (737)
Government (4493)
Grass and pollen (4)
Guidances (51)
Healthcare (19143)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (123)
Indications (27)
Infectious disease (2785)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (92)
Interviews (311)
IPO (16776)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (36)
Layoffs (489)
Leadership (17)
Legal (7982)
Liver cancer (73)
Lung cancer (309)
Lymphoma (141)
Machine learning (5)
Management (58)
Manufacturing (291)
MASH (65)
Medical device (13495)
Medtech (13500)
Mergers & acquisitions (19738)
Metabolic disorders (691)
Multiple sclerosis (77)
NASH (19)
Neurodegenerative disease (97)
Neuropsychiatric disorders (30)
Neuroscience (1964)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2565)
Now hiring (38)
Obesity (376)
Opinion (222)
Ovarian cancer (75)
Pain (84)
Pancreatic cancer (81)
Parkinson's disease (153)
Partnered (21)
Patents (225)
Patient recruitment (100)
Peanut (47)
People (58594)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21249)
Phase II (29842)
Phase III (22072)
Pipeline (1140)
Policy (138)
Postmarket research (2601)
Preclinical (9069)
Press Release (67)
Prostate cancer (101)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (396)
Real estate (6014)
Recruiting (66)
Regulatory (22668)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (73)
Series A (134)
Series B (87)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2220)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3758)
State (2)
Stomach cancer (14)
Supply chain (66)
Tariffs (24)
The Weekly (47)
United States (22596)
Vaccines (688)
Venture capitalists (40)
Weight loss (250)
Women's health (36)
Worklife (16)
Date
Today (35)
Last 7 days (496)
Last 30 days (2428)
Last 365 days (33909)
2025 (9471)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32347)
2015 (38398)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (237)
Arkansas (14)
Asia (39171)
Australia (6524)
California (5914)
Canada (1952)
China (500)
Colorado (260)
Connecticut (275)
Delaware (137)
Europe (85583)
Florida (864)
Georgia (203)
Idaho (57)
Illinois (531)
India (25)
Indiana (304)
Iowa (10)
Japan (151)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (877)
Massachusetts (4514)
Michigan (217)
Minnesota (384)
Mississippi (2)
Missouri (79)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1693)
New Mexico (30)
New York (1673)
North Carolina (1003)
North Dakota (7)
Northern California (2565)
Ohio (197)
Oklahoma (14)
Oregon (37)
Pennsylvania (1320)
Puerto Rico (11)
Rhode Island (31)
South America (1110)
South Carolina (20)
South Dakota (1)
Southern California (2220)
Tennessee (99)
Texas (880)
Utah (174)
Virginia (140)
Washington D.C. (61)
Washington State (552)
West Virginia (3)
Wisconsin (52)
713,191 Results for "protagonist therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.
March 3, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Protagonist Therapeutics Reports Granting of Inducement Award - April 16, 2025
April 17, 2025
·
2 min read
Press Releases
Protagonist Therapeutics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
March 19, 2025
·
6 min read
Press Releases
Protagonist Therapeutics Reports Granting of Inducement Awards
January 7, 2025
·
2 min read
Biotech Bay
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York City on June 4-6, 2024.
May 31, 2024
·
2 min read
Biotech Bay
Protagonist Therapeutics to Participate in Upcoming March 2024 Investor Conferences
Protagonist Therapeutics, Inc. announced that they will participate in three upcoming investor conferences.
March 6, 2024
·
2 min read
Press Releases
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
December 19, 2024
·
2 min read
Press Releases
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 24, 2025
·
13 min read
Press Releases
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
March 3, 2025
·
14 min read
Biotech Bay
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
Protagonist Therapeutics, Inc. announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024.
March 18, 2024
·
1 min read
1 of 71,320
Next
